Home Articles List Article Information
Medical Journal of Viral Hepatitis
Journal Archive
Volume Volume 8.2 (2024)
Volume Volume 8.1 (2024)
Volume Volume 7.3 (2023)
Volume Volume 7.2 (2023)
Volume Volume 7.1 (2022)
Volume Volume 6.3 (2022)
Volume Volume 6.2 (2022)
Volume Volume 6.1 (2021)
Volume Volume 5.3 (2021)
Volume Volume 5.2 (2021)
Volume Volume 5.1 (2020)
Volume Volume 4.2 (2020)
Volume Volume 4.1 (2019)
Volume Volume 3.2 (2019)
Volume Volume 3.1 (2018)
Volume Volume 2.2 (2018)
Volume Volume 2.1 (2016)
Volume Volume 1.2 (2016)
Volume Volume 1.1 (2015)
Nasser, M., Ahmed, A., Ilham, T., Tarek, S., Hassan, R., Ahmed, D., Atef, E., Farha, E. (2019). The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B. Medical Journal of Viral Hepatitis, 3.2(2), 57-64. doi: 10.21608/mjvh.2019.55731
Mousa Nasser; Abdel-Razik Ahmed; Talat qattan Ilham; sheta Tarek; Rizk Hassan; Deiab Ahmed; Elshazly Atef; Elshinawy Farha. "The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B". Medical Journal of Viral Hepatitis, 3.2, 2, 2019, 57-64. doi: 10.21608/mjvh.2019.55731
Nasser, M., Ahmed, A., Ilham, T., Tarek, S., Hassan, R., Ahmed, D., Atef, E., Farha, E. (2019). 'The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B', Medical Journal of Viral Hepatitis, 3.2(2), pp. 57-64. doi: 10.21608/mjvh.2019.55731
Nasser, M., Ahmed, A., Ilham, T., Tarek, S., Hassan, R., Ahmed, D., Atef, E., Farha, E. The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B. Medical Journal of Viral Hepatitis, 2019; 3.2(2): 57-64. doi: 10.21608/mjvh.2019.55731

The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B

Article 4, Volume 3.2, Issue 2, April 2019, Page 57-64  XML PDF (156.23 K)
Document Type: Original article
DOI: 10.21608/mjvh.2019.55731
View on SCiNiTO View on SCiNiTO
Authors
Mousa Nasser1; Abdel-Razik Ahmed1; Talat qattan Ilham2; sheta Tarek3; Rizk Hassan4; Deiab Ahmed4; Elshazly Atef5; Elshinawy Farha6
1Tropical Medicine dept, Faculty of Medicine, Mansoura Univ., Egypt.
2Medical Molecular Virology, Taibah University, KSA
3Internal Medicine dept., Faculty of Medicine, Mansoura Univ., Egypt.
4Internal Medicine dept., Faculty of Medicine, Mansoura Univ., Egypt
5Parasitology dept., Faculty of Medicine, Mansoura Univ., Egypt.
6Clinical pathology dept., ., Faculty of Medicine, Mansoura Univ., Egypt.
Abstract
Background: Schistosomiasis remains an important cause of
parasitic morbidity and mortality worldwide. In countries where
schistosomiasis is endemic, a high prevalence of combined
Schistosomiasis mansoni and chronic hepatitis C and chronic
hepatitis B co-infection has been described. The immunopathogenesis
of human schistosomiasis with or without chronic
hepatitis remains controversial. Aim of the work: Is to evaluate
the immunopathogenic role of Th1 cytokine (IL-2) and Th2
cytokine (IL-4) in patients with different stages of hepatointestinal
schistosomiasis with or without chronic hepatitis. Methods: The
study included 60 Egyptian patients with different stages of
hepatointestinal schistosomiasis. They include 40 patients with
hepatosplenic schistosomiasis (divided into 4 subgroups according
to stage of hepatosplenic schistosomiasis), 10 patients with
schistosoma mansoni and chronic hepatitis C and 10 patients
with schistosoma mansoni and chronic hepatitis B co-infection,
In addition to, 10 healthy controls. IL-2 and Il-4 was measured
by competitive enzyme immunoassay (EIA) which measures the
natural and recombinant forms of the cytokines. Results:
Compared to control group, patients with hepatosplenic schistosomiasis
showed significant increase in serum IL-2 from stage
1 (P< 0.05) to stage 4 (P< 0.001). Moreover, both groups with
combined schistosomiasis and chronic hepatitis C and chronic
hepatitis B showed significant increase in the IL-2 (P< 0.05 for
both). Furthermore, decompensated schistosomiasis showed
highly significant increase in the IL-2 versus compensated schistosomiasis
(P< 0.001). Also, compared to control group, patients
with hepatosplenic schistosomiasis showed significant increase
in serum IL-4, that decreased from stage 1 (P< 0.001)) to nonsignificant
increase in stage 4 (P> 0.05). In addition, chronic HCV
with schistosomiasis showed significant increase in the IL-4 (P<
0.05) and chronic HBV with schistosomiasis showing significant
increase in the IL-4 (P< 0.001). Moreover, compensated schistosomiasis
showed significant increase in the IL-4 (P< 0.001)
versus decompensated schistosomiasis. Conclusion: Patients
with chronic schistosomiasis present a mixed profile of Th1 and
Th2 cytokines. The Th1 (IL-2) was increased with the progression
of the hepatosplenic schistosomiasis from stage 1(hepatomegaly)
to the stage 4. However, The Th2 (IL-4) was elevated in the first
stage of hepstosplenic schistosomiasis and then decreased with
progression of the disease. In patients with combined schistosomiasis
and chronic hepatitis the Th2 (IL-4) is the predominant
cytokine versusTh1 (IL-2).
Keywords
Schistosomiasis; Chronic hepatitis; interleukin-2 and interleukin-4
Statistics
Article View: 198
PDF Download: 513